Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
SAN DIEGO, Feb. 11, 2016 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its fourth quarter and full year 2015 financial and operating results after the close of U.S. financial markets on Thursday, February 18, 2016. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | |
| Date: | February 18, 2016 |
| Time: | 4:30 pm Eastern Standard Time (1:30 pm Pacific Standard Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 44255837 |
| Via web: | www.traconpharma.com; “Events and Presentation” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer, wet age-related macular degeneration and fibrotic diseases. TRACON’s pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
